Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Nifty has more room to run; stay selective: Analysts
Indian stock markets are showing cautious optimism, with the Nifty eyeing the 24,300-25,000 zone amid ongoing volatility. Analysts recommend selective trading and specific strategies like a moderately bullish Call Spread. Top stock picks include TVS Motor, Samvardhana Motherson International, Oberoi Realty, Aurobindo Pharma, Vijaya Diagnostic Centre, and Mahindra & Mahindra Financial Services, each presenting unique buying opportunities with defined targets and stop losses.
Vijaya Diagnostic Centre CTO Sai Siva Prasad resigns
Vijaya Diagnostic Centre announced its chief technology officer (CTO), Sai Siva Prasad, has resigned from the services of the company due to personal reasons.
Vijaya Diagnostic CFO Ankit Shah resigns
Vijaya Diagnostic Centre announced the resignation of its chief financial officer (CFO), Ankit Shah.
Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs
Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.
Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
Vijaya Diagnostic Centre consolidated net profit rises 37.49% in the March 2026 quarter
Sales rise 26.63% to Rs 219.38 crore
Vijaya Diagnostic Centre: Excellent health report in Q4 FY26
This diagnostics player is well-positioned to compound earnings
Vijaya Diagnostic gains over 3% as Emkay reiterates buy, sees strong growth across key markets
The stock climbed as much as 5 percent to an intraday high of Rs 1,375.30 before trading at Rs 1,358.80, up 3.5 percent, in afternoon trade
Buy Vijaya Diagnostic; target of Rs 1400: Emkay Global Financial
Emkay Global Financial is bullish on Vijaya Diagnostic has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated Jun 24, 2026.